Vertical: HealthcareBase Year: 2018
Market Size (2018)
$29.70B
Projected (2025)
$89.36B
CAGR (2016–2025)
16.7%
Key Players
5+
Game-based neurorehabilitation systems have the potential to encourage patients in continuing rehabilitation exercises at home. The use of games in neurorehabilitation offers patients an opportunity to participate in an exercise program that is fun, engaging, and at the same time, beneficial to address their disabilities.
The factors leading to the growth of the global neurorehabilitation gaming systems market are increasing geriatric population, rising neurological diseases, and increasing product launches & approvals. However, stringent regulatory policies and requirements of skilled professionals are the posing hurdles to the market growth on the global level.
The Neurorehabilitation Gaming Systems Market market is projected to grow at a CAGR of 16.7% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansGame-based neurorehabilitation is the area of research pertaining to the use of technology within the field of physiotherapy. Irrespective of the cause of impairment, the main aim of most neurological rehabilitation is to facilitate learning or relearning of motor skills. Traditional rehabilitation is time-consuming and requires costly and lengthy sessions with therapists. Game-based neurorehabilitation systems have the potential to encourage patients in continuing rehabilitation exercises at home. The use of the games in neurorehabilitation offers patients an opportunity to participate in an exercise program that is fun, engaging, and at the same time, beneficial to address their disabilities. Current research indicates that the use of virtual reality as an adjunct to traditional rehabilitation is an economically beneficial approach and ensure optimal rehabilitation of patients with neurological disorders.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global neurorehabilitation gaming systems market is profitable, both for existing players as well as new entrants. A substantial level of rivalry is observed among the existing manufacturers in the market. Our analysis revealed that market players have adopted different strategies and innovative research & development techniques to expand their business and secure their position in the global neurorehabilitation gaming systems market. In recent years, strategic movements by major players included approvals, which have been used as market penetration strategies and a means to reduce competition.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on geographical expansion and product improvement. It has also been predicted that improvement of the global economic scenario, combined with efforts to enhance infrastructure, can fuel market growth, making it an ideal time to launch new products and increase the market presence.
Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies to stay abreast of emerging technologies that could affect the continuing competitiveness of their product lines in the market.
There are numerous players operating in this market all over the globe. Most of these players exist in the American and European regions. The major players in the global neurorehabilitation gaming system market are MindMaze, XRHealth, Microsoft Corporation, Neofect, and Barron Associates Inc.
MindMaze, headquartered in Lausanne in Switzerland, develops medical-grade virtual reality (VR) products to stimulate neural recovery. It develops a platform to build intuitive human-machine interfaces combining VR, computer graphics, brain imaging, and neuroscience. The company’s product MindMotion GO brings gamified neurorehabilitation, which offers real-time audio and visual feedback, to assess patient progress and performance. MindMotion GO is currently available in European markets and is cleared by the US Food and Drug Administration (FDA) in May 2018. MindMaze also received the FDA clearance for its MindMotion Pro platform, a motion capture system that can be used in rehabilitation of stroke and traumatic injury patients. Recently, MindMaze also acquired Neuro Motor Innovations, a company that also utilizes game therapy as a complementary treatment for stroke patients. The company’s innovative computing platform is helping to gain market dominance.
XRHealth (US) is the first VR/AR telehealth platform in the world that addresses a wide variety of neurocognitive, emotional, and physical symptoms. XRHealth is the first certified virtual reality medical company in the world, and all its medical Applications are FDA authorized. XRHealth specializes in developing medical tools and content while delivering real-time analytics. XRHealth entered in partnership with Healing Healthcare Systems, where participating hospitals could gain access to XRHealth’s VRHealth platform in 2019. These ongoing partnerships would help the company to gain maximum share in the market.
Microsoft Corporation (US) is a multi-national company that develops, manufactures, licenses supports, and sells computer software, consumer electronics, and personal computers and services. The company offers an array of services including cloud-based solutions that provide customers with software, services, platforms, and content as well as solution support and consulting services. Kinect is Microsoft’s motion sensor add-on for the Xbox 360 gaming console. Such product launches would help the company to get maximum share in the global neurorehabilitation gaming systems market.
Neofect is a US-based MedTech company. The company is engaged in developing innovative smart rehabilitation solutions to help patients with neurological and musculoskeletal injuries. High customer satisfaction level, exceptional performance in new markets, and strong brand portfolio add to the company’s competitive advantage within the global neurorehabilitation gaming systems market.
Barron Associates Inc. is a research & development company based in the US. The company is focused on providing novel solutions such as intelligent and adaptive technologies in the market. The company offers a wide range of software and hardware products and services to various sectors including aerospace, health systems, science, and defense sectors. In June 2017, Barron Associates Inc. launched the SaeboVR product under the marketing and distribution agreement with Saebo, Inc. (US). This helped it to strengthen its rehabilitation product portfolio. SaeboVR is an FDA-cleared and CE-marked software system used with Microsoft Kinect, which supports in repetitive task practice for rehabilitation of adults in a clinical or home setting. Such an innovative product platform would help the company to capture the maximum share in the market.
Threat of New Entrants
The threat of new entrants is moderate to high in the global neurorehabilitation gaming systems market. Any neurorehabilitation gaming systems developing company trying to enter the market are required to accept or abide by the mandatory regulatory standards. The neurorehabilitation gaming systems market was also characterized by a reasonable degree of brand loyalty, which is now turning out that the end users are opting for new software demos instead of choosing the most popular software. Moreover, the increasing use of technology in the healthcare industry is influencing many of the start-ups to take a keen interest in the field of healthcare IT, which increases the possibility of new entrants in the market.
Bargaining Power of Suppliers
The suppliers in the global neurorehabilitation gaming systems industry are the developers of the neurorehabilitation gaming systems. There is a limited number of suppliers in the global neurorehabilitation gaming systems market, which leads to a moderate amount of bargaining power in the market. Additionally, the switching cost of these suppliers is low as suppliers tend to enter into long term associations with the software developers. However, some companies in developing countries offer the software at a relatively lower price due to low healthcare expenditure, which reduces the profit potential of the neurorehabilitation gaming systems industry.
Threat Of Substitutes
The threat of substitutes in the global neurorehabilitation gaming systems market is low. There are very a smaller number of substitutes present for the neurorehabilitation gaming systems that pose a moderate threat to the global neurorehabilitation gaming systems market. Buyers’ inclination towards substitutes is low due to their less availability. Additionally, the high degree of switching cost minimizes the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of buyers is low in the global neurorehabilitation gaming systems market. The market consists of a limited number of buyers, including neurological patients. Furthermore, the market is characterized by a low degree of brand identity. Moreover, the buyers can exert moderate pressure on the neurorehabilitation gaming systems developers as they already provide high-quality software. Therefore, due to a moderate level of services provided by the neurorehabilitation gaming systems manufacturers, the bargaining power of suppliers tends to be low.
Intensity Of Rivalry
The degree of competition in the neurorehabilitation gaming systems market is low to moderate. The restrained degree of product differentiation among existing players increases the intensity of rivalry in the market. Neurorehabilitation gaming systems developing companies are trying to create less expensive systems to make procedures more affordable in developing regions. To overcome the competition, players are engaged in developing low-cost solutions. Moreover, the players are more focused on developing advanced systems to overcome their rivals.
Market estimates by geography (2025)
InsightAmericas leads with $39.25B by 2025, while Asia Pacific is projected to grow fastest at a 16.9% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Americas | $9.69B | $20.76B | $39.25B | 16.8% | 44% |
| Asia Pacific | $4.18B | $9.00B | $17.08B | 16.9% | 19% |
| Europe | $6.42B | $13.69B | $25.79B | 16.7% | 29% |
| Rest of the World | $1.97B | $4.01B | $7.24B | 15.5% | 8% |
| Total | $22.27B | $47.44B | $89.36B | 16.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$89.36B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Hardware | $61.14B | 16.9% | 68% |
| Software | $28.22B | 16.2% | 32% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Neurorehabilitation Gaming Systems Market covering market dynamics, competitive landscape, and strategic outlook.
The Neurorehabilitation Gaming Systems Market market is projected to reach $89.36B by 2025, growing at 16.7% CAGR. The Hardware segment holds the largest share.
The use of virtual reality (VR) as an adjunct to traditional rehabilitation in neurological patients is promising. Consoles and tablets are commercially available, affordable, and safe to use to supplement rehabilitation of neurological conditions. Games applied in the field of neurorehabilitation are helping to improve the process of motor learning and recovery from incidents of stroke, traumatic brain injury, and other neuromuscular impairment by increasing user motivation during training. However, these systems are still rarely adopted at patients’ homes. Discovering and eliminating the obstacles in promoting game-based rehabilitation at home is therefore essential.
Rising neurological disorders, the effectiveness of the gaming system in neurorehabilitation, surge in the geriatric population, and increasing product launches and approvals by key players are expected to drive the growth of the neurorehabilitation gaming systems market. However, stringent regulatory policies and requirements of skilled professionals are expected to hamper the growth of the market.
The market is expected to witness a profitable growth owing to the rise in neurological disorders such as Parkinson’s, Alzheimer’s, stroke, epilepsy, multiple sclerosis, and essential tremors. Stroke is the third leading cause of death in the US. More than 140,000 people die each year from stroke in the country. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked. As per the statistics of the World Health Organization (WHO), an estimated 5 million people are diagnosed with epilepsy each year globally. Additionally, every year, approximately 250,000 to 500,000 people suffer a spinal cord injury (SCI) around the world. Furthermore, the Multiple Sclerosis Society UK estimated that there are around 100,000 people with multiple sclerosis (MS) in the UK and each year, 5,000 people are newly diagnosed with the condition.
Neurodegenerative disorders may lead to persistent or permanent functional limitations, including paralysis, abnormal control of movements, loss of coordination, loss of range of motion, abnormal posture, spasticity, memory deficits, spatial neglect, aphasia, and dyspraxia, among others. This functional limitation severely impacts a person’s ability to perform activities of daily living. The rehabilitation of neurological disorder requires repetitive, intensive, and goal-oriented therapy. Virtual reality (VR) has the potential to satisfy these requirements. Game-based therapy can promote patients' engagement in rehabilitation therapy as an interesting and motivating tool.
Thus, the rise in neurological disorders has heightened the demand for neurorehabilitation gaming systems, which is positively influencing the growth of the market.
The rehabilitation gaming system offers a powerful opportunity to increase patient motivation and adherence to training in neurorehabilitation but is currently limited in its systemic applicability. For successful implementation of games in mainstream rehabilitation programs, there is a need for the development of an integrated rehabilitation software platform that supports existing systemic relationships and methodologies. At present, a major criticism of existing gaming scenarios for rehabilitation is that they have been designed primarily by engineers, scientists, and health professionals. They intend to build and test the overall functionality of specific research-based hardware. The games themselves often lack the qualities required to be motivational for patients for the long-term. It is extremely important to keep the level of challenge optimal to stimulate intrinsic motivation during training. The task should be presented playfully and should elicit a game-like experience, but it should be designed to reflect the daily activities of the user, while the parameters recorded should be determined based on the neurorehabilitation practice. Moreover, there is a need for increased awareness among people suffering from neurological disorders about the neurorehabilitation gaming system. This is likely to create an opportunity for the manufacturers to develop innovative gaming platforms which suits diverse needs of user.
The manufacturing of neurorehabilitation systems follows crucial steps and processes. These processes differ from the manufacturer, country regulations, the adoption rate of the country, and the pricing of devices in the region. Companies must comply with the Food and Drug Administration (FDA) regulations in the US and CE mark in the EU to launch their products in respective regions. In some economies such as Japan and China regulatory processes are given utmost importance. The healthcare regulatory authorities of these countries employ strict policies and processes for the approval of products. In November 2014, the Japanese pharmaceutical and medical device market underwent significant changes due to the replacement of the Japanese Pharmaceutical Affairs Law (JPAL) with the new Pharmaceutical and Medical Device Act (PMD Act). The PMD Act affects major areas of medical device regulations, including quality management system compliance, device registration, the regulation of medical software, and third-party certifications. To market medical devices in Japan, manufacturers must be compliant with the current PMD Act.
This changing regulatory scenario is restricting manufacturers to produce neurorehabilitation gaming systems in different regions, and this may act as a factor that would curb the growth of the market in the future.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Neurorehabilitation Gaming Systems Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Company Headquarters: California, US Founded: 2010 Workforce: ~50-200 Company Working: Neofect develops innovative smart rehabilitation solutions to help patients with neurological and musculoskeletal injuries. Neofect utilizes portable, lightweight, and affordable equipment to perform training exercises. Its smart rehabilitation solutions are designed to allow therapy training through games. The company offers clinically proven rehab programs customized to each patient for a faster recovery. Neofect smart rehabilitation solutions are developed by utilizing clinical evidence, which provides optimal therapies for each patient on the basis of proprietary algorithms and clinical data. It also reflects the patient’s personal motivation to maximize their rehabilitation training. Neofect was awarded the VirtualTech award and MedTech Breakthrough award for its Smart Board for Home NextGen. It is a gamified rehabilitation device for stroke patients to be used at home.
Company Headquarters: Boston, US Founded: 2016 Workforce: ~11-50 Company Working: XRHealth is the first VR/AR Telehealth platform in the world. XR stands for Extended Reality and includes Virtual Reality (VR), Augmented Reality (AR), and Mixed Reality (MR). The company’s telehealth platform provides innovative, immersive, and therapeutic applications that address a wide variety of neurocognitive, emotional, and physical symptoms. These applications are combined with an advanced data portal that utilizes artificial intelligence (AI) and cloud-computing algorithms to deliver meaningful data analytics for monitoring and managing patients remotely. The platform enables two-way interactions between patients and healthcare providers. The VR/AR telehealth platform of XRHealth is ISO certified, FDA certified, and HIPAA compliant.
Company Headquarters: Lausanne, Switzerland Founded: 2012 Workforce: ~200 Company Working: MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions dedicated to accelerating the brain's ability to recover, learn, and adapt. It is a medical device company that specializes in neurorehabilitation, virtual reality, brain imaging, neurotechnology, 3D technology, neural prediction, brain computer interface, and engineering. It works at the intersection of neuroscience, bio-sensing, engineering, mixed reality, and artificial intelligence. Its healthcare division is addressing some of neurology's most difficult problems, such as stroke, Alzheimer's disease, and Parkinson's disease, by developing a universal platform for brain health and recovery and novel digital therapeutic interventions. MindMaze's ground-breaking FDA-cleared and CE-marked neuro-digital therapeutics help patients recover from a wide range of critical neurological conditions. It is Switzerland's first unicorn, with offices in Lausanne, Baltimore, London, Paris, and Mumbai.
Company Headquarters: Montreal, Canada Founded: 2010 Workforce: 11-50 Company Working: Jintronix was founded in 2010 to leverage motion capture technology and transform physical rehabilitation. The company offers an innovative solution in the area of physical therapy. Jintronix is developing a cost-effective physical rehabilitation software for hospitals, clinics, and home use. It works to assist with the delivery of physical therapy by leveraging Kinect technology and brings together themes that are resonating with therapists, physicians, and patients around the world. The company’s unique telemedicine service allows patients to practice clinically designed rehabilitation exercises from anywhere. In the case of long-distance patients, this telemedicine platform allows therapists to assign exercises and monitor patient's progress in mobility. It received 510(k) clearance from the US Food and Drug Administration (FDA) for the Jintronix rehabilitation system. Currently, the Jintronix program is available in 10 different countries.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
